TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18439196

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (5-7 minutes, adapted from classic motivational interviewing techniques)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 292
Study: 16682403

Group type: EXPERIMENTAL
Intervention: GnRH agonist (0.5 mg buserelin)
Number of subjects: 69

Group type: COMPARATOR
Intervention: hCG (10,000 IU)
Number of subjects: 69
Study: 12791434

Group type: EXPERIMENTAL
Intervention: 30 mg memantine/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10686270

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (.5 mg/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 7
Study: 9315417

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal film containing 19 mg BZK
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal film containing 25 mg BZK
Number of subjects: 10

Group type: COMPARATOR
Intervention: VCF containing 70 mg N‐9
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline cycles (no film used)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Colposcopy with BZK films
Number of subjects: 10

Group type: COMPARATOR
Intervention: Colposcopy with VCF
Number of subjects: 10

Group type: COMPARATOR
Intervention: Colposcopy in baseline cycles
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acceptability of films
Number of subjects: 10
Study: 1586375

Group type: EXPERIMENTAL
Intervention: Preparation A (40 mg slow-release isosorbide mononitrate)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Preparation B (40 mg slow-release isosorbide mononitrate)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation C (40 mg slow-release isosorbide mononitrate)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure and heart rate (pharmacodynamic effects)
Number of subjects: 18
Study: 3991283

Group type: EXPERIMENTAL
Intervention: 100% reimbursement for health costs
Number of subjects: 1136

Group type: COMPARATOR
Intervention: 95% cost-sharing
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Preventive care treatment episodes
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Hospital expenditures
Number of subjects: 1136
Study: 28952800

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Any anti-binge drinking messages (loss-framed or gain-framed)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no messages)
Number of subjects: 156
Study: 26354383

Group type: EXPERIMENTAL
Intervention: Mixed meal (550 kcal)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Glucose challenge alone
Number of subjects: 36
Study: 25066449

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24343979

Group type: EXPERIMENTAL
Intervention: Psychoeducation and problem solving (PEPS) trial
Number of subjects: 90
Study: 20543706

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy initiated a median of 7 weeks before delivery (cohort A)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Zidovudine from 34 to 36 weeks gestation until delivery with single-dose nevirapine in labor (cohort B)
Number of subjects: 248
Study: 18950302

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing
Number of subjects: 451

Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 451

Group type: COMPARATOR
Intervention: Closed loop (CLS) pacing
Number of subjects: 451
Study: 15957509

Group type: EXPERIMENTAL
Intervention: Valacyclovir (3000 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 12527967

Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Field running
Number of subjects: 0
Study: 10407231

Group type: EXPERIMENTAL
Intervention: Summary statistics
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Repeated measures analysis of variance (RMAOV)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Marginal models (generalized estimating equation methodology)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Multilevel models (hierarchical random effects models)
Number of subjects: 240
Study: 8890680

Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2062621

Group type: EXPERIMENTAL
Intervention: HbOC vaccine (three doses at 2, 4, and 6 months of age)
Number of subjects: 20800

Group type: EXPERIMENTAL
Intervention: HbOC vaccine (two doses)
Number of subjects: 20800

Group type: EXPERIMENTAL
Intervention: HbOC vaccine (one dose)
Number of subjects: 20800
Study: 6203496

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Electroconvulsive treatments (ECTs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Different antidepressant treatments
Number of subjects: 21
Study: 30328701

Group type: EXPERIMENTAL
Intervention: Targeted education
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 67
Study: 30051571

Group type: EXPERIMENTAL
Intervention: Eliava Pyophage (monospecies counterpart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phage cocktail
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27319097

Group type: EXPERIMENTAL
Intervention: Epidural Droperidol
Number of subjects: 86

Group type: COMPARATOR
Intervention: Epidural Adrenaline
Number of subjects: 86
Study: 25282871

Group type: EXPERIMENTAL
Intervention: 12-week self-administered weight lifting program
Number of subjects: 23
Study: 22780937

Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg per week for 6 weeks), palitaxel liposome 160 mg/m2, and carboplatin (AUC = 6)
Number of subjects: 41

Group type: COMPARATOR
Intervention: LP regimen (palitaxel liposome and carboplatin)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus LP regimen
Number of subjects: 41

Group type: COMPARATOR
Intervention: LP regimen
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 20547990

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anastrozole vs Tamoxifen
Number of subjects: 0
Study: 15984909

Group type: EXPERIMENTAL
Intervention: Trimetazidine 20mg three times daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 12860863

Group type: EXPERIMENTAL
Intervention: NT pro BNP above median concentration
Number of subjects: 87

Group type: COMPARATOR
Intervention: NT pro BNP below median concentration
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Relaxin above median concentration
Number of subjects: 87

Group type: COMPARATOR
Intervention: Relaxin below median concentration
Number of subjects: 87
Study: 11776548

Group type: EXPERIMENTAL
Intervention: Oxygen-conserving nasal cannula (CNC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen-conserving nasal cannula (CNC) at 0.5 L/min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen-conserving nasal cannula (CNC) at 1.0 L/min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen-conserving nasal cannula (CNC) at 1.5 L/min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen-conserving nasal cannula (CNC) at 2.0 L/min
Number of subjects: 0
Study: 8526700

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment intervention started before hospital discharge and continued at home
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment intervention
Number of subjects: 354
Study: 10149803

Group type: EXPERIMENTAL
Intervention: High-resolution B-mode ultrasound imaging
Number of subjects: 16000
Study: 6839666

Group type: EXPERIMENTAL
Intervention: Static handgrip
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dynamic handgrip
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control conditions (without drugs)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Autonomic blockade (atropine and metoprolol)
Number of subjects: 6
Study: 29254367

Group type: EXPERIMENTAL
Intervention: Group intervention program (four weekly sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 60
Study: 28721992

Group type: EXPERIMENTAL
Intervention: Intra-pocket 20% benzocaine gel
Number of subjects: 15

Group type: COMPARATOR
Intervention: Infiltration/block by 2% lidocaine with 1:80,000 adrenaline
Number of subjects: 15
Study: 26700836

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) alone (n = 78)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Full defragmentation (full defrag) approach (n = 75)
Number of subjects: 205
Study: 23915222

Group type: EXPERIMENTAL
Intervention: Contingency manipulation in the computerized task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Similarity manipulation in the computerized task
Number of subjects: 0
Study: 21423021

Group type: EXPERIMENTAL
Intervention: Genotype-informed dosing algorithms
Number of subjects: 230

Group type: COMPARATOR
Intervention: Clinical dosing algorithms
Number of subjects: 230
Study: 18503551

Group type: EXPERIMENTAL
Intervention: Topically applied 5% vitamin C and 0.1% madecassoside
Number of subjects: 20
Study: 16341856

Group type: EXPERIMENTAL
Intervention: LI 160 (HYF 41 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SJW powder tablets 2.7 g/day (HYF 12 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SJW powder tablets 2.7 g/day (HYF 0.13 mg/day)
Number of subjects: 42
Study: 12894080

Group type: EXPERIMENTAL
Intervention: Topical nitrogen mustard
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6
Study: 11145006

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 93
Study: 8854742

Group type: EXPERIMENTAL
Intervention: Attended tone pips
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonattended tone pips
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All tone pips
Number of subjects: 0
Study: 1371341

Group type: EXPERIMENTAL
Intervention: Intervention (Infant Health and Development Program)
Number of subjects: 985

Group type: COMPARATOR
Intervention: Control (pediatric follow-up and referral services only)
Number of subjects: 985
Study: 6661512

Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride (2 X 40 mg)
Number of subjects: 10
Study: 29458343

Group type: EXPERIMENTAL
Intervention: HAART adherence
Number of subjects: 792
Study: 27455419

Group type: EXPERIMENTAL
Intervention: Water exercises rehabilitation program
Number of subjects: 192

Group type: COMPARATOR
Intervention: Kinesitherapy and low-frequency magnetic field rehabilitation program
Number of subjects: 192
Study: 24100464

Group type: EXPERIMENTAL
Intervention: Plyometric training (24 sessions over 8 weeks, 3 sessions per week)
Number of subjects: 36
Study: 22105879

Group type: EXPERIMENTAL
Intervention: MGuard net protective stent (MGS) implantation
Number of subjects: 556

Group type: COMPARATOR
Intervention: Manual thrombectomy (MT) pretreatment followed by bare-metal stent (BMS) implantation
Number of subjects: 556
Study: 20832848

Group type: EXPERIMENTAL
Intervention: Prebiotic formula group (formula containing a specific mixture of neutral oligosaccharides and pectin-derived acidic oligosaccharides)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Control formula group (regular formula without oligosaccharides)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Breast-feeding group
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Prebiotic formula group
Number of subjects: 414
Study: 18664348

Group type: EXPERIMENTAL
Intervention: Scalp-acupuncture
Number of subjects: 92

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 92
Study: 17038251

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 12355570

Group type: EXPERIMENTAL
Intervention: Lidocaine preparations with laser assistance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10336914

Group type: EXPERIMENTAL
Intervention: VDD pacemaker
Number of subjects: 441

Group type: COMPARATOR
Intervention: DDD pacemaker
Number of subjects: 441

Group type: COMPARATOR
Intervention: Both VDD and DDD pacemakers
Number of subjects: 441
Study: 7528712

Group type: EXPERIMENTAL
Intervention: FK506 (Tacrolimus) treatment without cellular rejection
Number of subjects: 17

Group type: COMPARATOR
Intervention: FK506 (Tacrolimus) treatment with cellular rejection
Number of subjects: 17
Study: 2168586

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1200 mg daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 6159865

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride treatment for 3 weeks
Number of subjects: 0
Study: 31449156

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients after a protein meal
Number of subjects: 301

Group type: COMPARATOR
Intervention: Healthy volunteers (HVs)
Number of subjects: 301
Study: 30729346

Group type: EXPERIMENTAL
Intervention: Supragingival debridement (SD) with adjunctive full mouth glycine powder air polishing (FM‐GPAP) (test, n = 42)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Supragingival debridement (SD) alone (control, n = 45)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 87
Study: 28938500

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Fecal immunochemical testing (FIT)
Number of subjects: 1497
Study: 25981758

Group type: EXPERIMENTAL
Intervention: Lumacaftor (600 mg once daily or 400 mg every 12 hours) in combination with ivacaftor (250 mg every 12 hours)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor groups
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1108
Study: 24268876

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pessary treatment
Number of subjects: 0
Study: 21633072

Group type: EXPERIMENTAL
Intervention: Weight gain velocity between 12 and 34 months
Number of subjects: 10494
Study: 19375250

Group type: EXPERIMENTAL
Intervention: Valproate treatment (1500 mg/day by Day 6)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Valproate treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 17525387

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rt-PA) started at 0.6 mg/kg over 30 minutes, followed by additional rt-PA via EKOS micro-infusion catheter or standard microcatheter up to a total dose of 22 mg over 2 hours.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intravenous recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined intravenous and intra-arterial approach
Number of subjects: 81
Study: 15453848

Group type: EXPERIMENTAL
Intervention: Silicone IOL (SI40NB, Allergan)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: AcrySof IOL (MA60BM, Alcon)
Number of subjects: 119
Study: 11584084

Group type: COMPARATOR
Intervention: High folate diet
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low folate diet
Number of subjects: 37
Study: 9706855

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine mouthrinse (0.1%)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 42
Study: 7886652

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (20 micrograms/puff)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flutropium bromide (30 micrograms/puff)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (100 micrograms/puff)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms/puff)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2190927

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg quotid. enalkiren
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg q.i.d. enalkiren
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 27828

Group type: EXPERIMENTAL
Intervention: Thienodiazepine (clotiazepam)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo or no treatment not explicitly mentioned)
Number of subjects: 40
Study: 31814140

Group type: EXPERIMENTAL
Intervention: mHealth application for wound care
Number of subjects: 70

Group type: COMPARATOR
Intervention: Verbal instructions and a booklet (Control)
Number of subjects: 70
Study: 30707210

Group type: EXPERIMENTAL
Intervention: Early protocolized rehabilitation (consultation of physical therapy, occupational therapy, and speech and language therapy within 72 hours of ICU admission, n = 26)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care (consultation per treating team, n = 32)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Early protocolized rehabilitation
Number of subjects: 58
Study: 26059899

Group type: EXPERIMENTAL
Intervention: D2 supplementation (100 IU/kg daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: D3 supplementation (100 IU/kg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (100 IU/kg daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (D2 and D3)
Number of subjects: 50
Study: 25317722

Group type: EXPERIMENTAL
Intervention: Oral application of 5 mL CHX 0.12% solution before intubation
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (no CHX before intubation)
Number of subjects: 314
Study: 23688526

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 1234
Study: 21828387

Group type: EXPERIMENTAL
Intervention: 3.5% menthol gel
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ice (0.5 kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 17
Study: 19903643

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) followed by low-level diode laser treatment for 5 days (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) followed by low-level diode laser treatment for 10 days (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) on a single quadrant per day for four consecutive days, followed by rescaling on the fifth day (Group A)
Number of subjects: 60
Study: 17100678

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 66
Study: 12831591

Group type: EXPERIMENTAL
Intervention: HMG
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: rFSH
Number of subjects: 10
Study: 9921711

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (aim: aPTT approximately 2 x normal)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 56
Study: 8677862

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1749

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749
Study: 1984373

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiopental 4 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiopental 6.5 mg/kg
Number of subjects: 40
Study: 6412673

Group type: EXPERIMENTAL
Intervention: 2 mg of sodium cromoglycate (SCG) aerosol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4 mg of sodium cromoglycate (SCG) aerosol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 or 4 mg of sodium cromoglycate (SCG) aerosol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3894841

Group type: EXPERIMENTAL
Intervention: Betahistine dimesilate 36 mg daily for at least six weeks
Number of subjects: 40
Study: 29291739

Group type: EXPERIMENTAL
Intervention: KM2H2 plus standard care
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 450
Study: 27739262

Group type: EXPERIMENTAL
Intervention: Carica papaya leaf extract (CPLE) administered three times daily for five days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard management guidelines for dengue (Control group)
Number of subjects: 300
Study: 24674234

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX), N=61
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo, N=24
Number of subjects: 85
Study: 23183732

Group type: EXPERIMENTAL
Intervention: Girls in school
Number of subjects: 665

Group type: COMPARATOR
Intervention: Girls not in school
Number of subjects: 665
Study: 20530518

Group type: EXPERIMENTAL
Intervention: Standard dose of dalteparin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Half-dose of dalteparin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 8
Study: 19002344

Group type: EXPERIMENTAL
Intervention: acitretin-narrow-band TL-01 phototherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: acitretin-psoralen plus ultraviolet A (acitretin-PUVA)
Number of subjects: 60
Study: 16169400

Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine (LAC) 3 g/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined L-carnitine (LC) 2 g/d and L-acetylcarnitine (LAC) 1 g/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12501022

Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 5